Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urapidil-induced hemodynamic changes in humans.

E Bielen1, R Fagard, J Staessen

  • 1Department of Pathophysiology, University of Leuven, Belgium.

The American Journal of Cardiology
|August 15, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drievoudige Antihypertensive Behandeling.

Acta clinica Belgica·2016
Same author

Feasibility of Adequate Thrombolytic Therapy with Streptokinase in Peripheral Arterial Occlusions: II. Changes in Peripheral Blood and Thrombolysis in vivo.

British medical journal·2010
Same author

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.

Epilepsia·2000
Same author

Power spectral analysis of RR interval and blood pressure short-term variability at rest and during dynamic exercise: comparison between cyclists and controls.

International journal of sports medicine·1996
Same author

A consensus view on the technique of ambulatory blood pressure monitoring. The Fourth International Consensus Conference on 24-Hour Ambulatory Blood Pressure Monitoring.

Hypertension (Dallas, Tex. : 1979)·1995
Same author

Prognostic value of training-induced change in peak exercise capacity in patients with myocardial infarcts and patients with coronary bypass surgery.

The American journal of cardiology·1995

Urapidil effectively lowers blood pressure in hypertensive and normal subjects by blocking alpha 1-adrenoceptors and potentially stimulating 5-HT1A receptors. It improves hemodynamics, particularly in patients with pulmonary hypertension.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hypertension Research

Background:

  • Urapidil is an antihypertensive agent with a dual mechanism of action.
  • Its effects involve peripheral alpha 1-adrenoceptor blockade and potential central 5-hydroxytryptamine1A (5-HT1A)-receptor stimulation.

Purpose of the Study:

  • To investigate the hypotensive and hemodynamic effects of urapidil in various patient populations.
  • To assess acute and chronic hemodynamic changes induced by urapidil.

Main Methods:

  • Administration of urapidil to hypertensive patients, normal subjects, and animal models.
  • Measurement of systemic vascular resistance, cardiac output, heart rate, stroke volume, and pulmonary hemodynamics.
  • Evaluation of forearm, renal, and splanchnic blood flow.

Related Experiment Videos

Main Results:

  • Urapidil demonstrated a hypotensive action in both hypertensive and normal subjects, primarily via peripheral alpha 1-adrenoceptor blockade.
  • Acute administration led to decreased pulmonary artery pressure and vascular resistance in pulmonary hypertension patients.
  • Significant increases in forearm, renal, and splanchnic flow were observed in essential hypertension patients.

Conclusions:

  • Urapidil effectively reduces systemic vascular resistance and improves hemodynamics in various cardiovascular conditions.
  • The drug shows promise in managing pulmonary hypertension and essential hypertension.
  • Chronic hemodynamic effects require further investigation, though systemic vascular resistance remains decreased.